Doyle Mittie bought AVTX
April 6, 2026 · Form 4 insider transaction
Doyle Mittie bought 3,970 shares of Avalo Therapeutics, Inc. at $12.65 per share, a transaction worth $50.2K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
3,970
Price
$12.65
Total value
$50.2K
InsiderDoyle Mittie
RoleOfficer, Director
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateApril 6, 2026
Filing dateApril 8, 2026
Shares owned after7,592
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.